Tasquinimod
CAS: 254964-60-8
Rif. 3D-FT76139
1mg | Fuori produzione | ||
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione |
Informazioni sul prodotto
- 1,2-Dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide
- 3-Quinolinecarboxamide, 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-
- 4-Hydroxy-5-methoxy-N-methyl-1-methyl-2-oxo-N-(4-trifluoromethylphenyl)-1,2-dihydroquinoline-3-carboxamide
- Abr 215050
- Abr-5050
- N-Methyl-N-(4-trifluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carboxamide
Tasquinimod is a cytostatic agent that binds to the Toll-like receptor, which is an innate immune receptor that plays a role in the regulation of inflammation. It is also a potent inhibitor of matrix metalloproteinase (MMP)-9 activity, which is important for tumor invasion and metastasis. Tasquinimod has been shown to inhibit tumor cell proliferation and induce apoptosis in various types of cancer cells including prostate cancer. This drug has minimal toxicity and does not affect healthy cells. Tasquinimod can be used to treat solid tumours such as prostate cancer.